Evidence map›Paper›PMID 34164387›Full record

ReviewFrontiers in bioengineering and biotechnology2021

Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine.

Sharanya Sankar, Kate O'Neill, Maurice Bagot D'Arc, Florian Rebeca, Marie Buffier, Elton Aleksi, Melanie Fan, Noriaki Matsuda, Eun Seok Gil, Lisa Spirio

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06698419 (A Prospective Study), which is not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06698419 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Prospective Study: The Effect of RADA16 on Mastoid Cavity Epithelialization After Canal Wall Down Mastoidectomy

TypeinterventionalSponsorUniversity of FloridaRan2025 to 2027Enrolled14ConditionsDelayed Wound HealingArmsRADA16 gel application into mastoid cavity
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 114 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Hemostasis: Role of PuraStatWorld journal of gastrointestinal endoscopy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sharanya Sankar3-D Matrix Europe SAS, Caluire-et-Cuire, France.
Kate O'Neill3-D Matrix UK Ltd., London, United Kingdom.
Maurice Bagot D'ArcBLUEPHARM SAS, Paris, France.
Florian Rebeca3-D Matrix Europe SAS, Caluire-et-Cuire, France.
Marie Buffier3-D Matrix Europe SAS, Caluire-et-Cuire, France.
Elton Aleksi3-D Matrix Inc., Newton, MA, United States.
Melanie Fan3-D Matrix UK Ltd., London, United Kingdom.
Noriaki Matsuda3-D Matrix, Ltd., Tokyo, Japan.
Eun Seok Gil3-D Matrix Inc., Newton, MA, United States.
Lisa Spirio3-D Matrix Inc., Newton, MA, United States.
Matrix Research (United States) · US3-D Matrix (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RADA16 is a synthetic peptide that exists as a viscous solution in an acidic formulation. In an acidic aqueous environment, the peptides spontaneously self-assemble into β-sheet nanofibers. Upon exposure and buffering of RADA16 solution to the physiological pH of biological fluids such as blood, interstitial fluid and lymph, the nanofibers begin physically crosslinking within seconds into a stable interwoven transparent hydrogel 3-D matrix. The RADA16 nanofiber hydrogel structure closely resembles the 3-dimensional architecture of native extracellular matrices. These properties make RADA16 formulations ideal topical hemostatic agents for controlling bleeding during surgery and to prevent post-operative rebleeding. A commercial RADA16 formulation is currently used for hemostasis in cardiovascular, gastrointestinal, and otorhinolaryngological surgical procedures, and studies are underway to investigate its use in wound healing and adhesion reduction. Straightforward application of viscous RADA16 into areas that are not easily accessible circumvents technical challenges in difficult-to-reach bleeding sites. The transparent hydrogel allows clear visualization of the surgical field and facilitates suture line assessment and revision. The shear-thinning and thixotropic properties of RADA16 allow its easy application through a narrow nozzle such as an endoscopic catheter. RADA16 hydrogels can fill tissue voids and do not swell so can be safely used in close proximity to pressure-sensitive tissues and in enclosed non-expandable regions. By definition, the synthetic peptide avoids potential microbiological contamination and immune responses that may occur with animal-, plant-, or mineral-derived topical hemostats.

Indexed as

endoscopyhemostasisnanofiberRADA16self-assembling peptide hydrogelsurgerytissue regenerationwound healing

Identifiers

PMID34164387
PMCPMC8216384
OpenAlexW3171984534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.